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Background: It has recently emerged that common epithelial cancers such as breast cancers have fusion genes like
those in leukaemias. In a representative breast cancer cell line, ZR-75-30, we searched for fusion genes, by analysing
genome rearrangements.
Results: We first analysed rearrangements of the ZR-75-30 genome, to around 10kb resolution, by molecular
cytogenetic approaches, combining array painting and array CGH. We then compared this map with genomic
junctions determined by paired-end sequencing. Most of the breakpoints found by array painting and array CGH
were identified in the paired end sequencing—55% of the unamplified breakpoints and 97% of the amplified
breakpoints (as these are represented by more sequence reads). From this analysis we identified 9 expressed fusion
genes: APPBP2-PHF20L1, BCAS3-HOXB9, COL14A1-SKAP1, TAOK1-PCGF2, TIAM1-NRIP1, TIMM23-ARHGAP32, TRPS1-LASP1,
USP32-CCDC49 and ZMYM4-OPRD1. We also determined the genomic junctions of a further three expressed fusion
genes that had been described by others, BCAS3-ERBB2, DDX5-DEPDC6/DEPTOR and PLEC1-ENPP2. Of this total of 12
expressed fusion genes, 9 were in the coamplification. Due to the sensitivity of the technologies used, we estimate
these 12 fusion genes to be around two-thirds of the true total. Many of the fusions seem likely to be driver
mutations. For example, PHF20L1, BCAS3, TAOK1, PCGF2, and TRPS1 are fused in other breast cancers. HOXB9 and
PHF20L1 are members of gene families that are fused in other neoplasms. Several of the other genes are relevant to
cancer—in addition to ERBB2, SKAP1 is an adaptor for Src, DEPTOR regulates the mTOR pathway and NRIP1 is an
estrogen-receptor coregulator.
Conclusions: This is the first structural analysis of a breast cancer genome that combines classical molecular
cytogenetic approaches with sequencing. Paired-end sequencing was able to detect almost all breakpoints, where
there was adequate read depth. It supports the view that gene breakage and gene fusion are important classes of
mutation in breast cancer, with a typical breast cancer expressing many fusion genes.
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In the last few years it has emerged that the common
epithelial cancers, such as carcinoma of breast, prostate
and lung, have fusion genes like those long associated
with leukaemias, lymphomas and sarcomas [1,2]. The
first to be discovered were in prostate cancer, where
about half of all cases have the TMPRSS2-ERG fusion
gene [3,4], and lung cancer, where around 5% of lung
cancers have a fusion that activates the ALK tyrosine
kinase, the EML4-ALK fusion [5]. However, these early
examples were found by essentially ‘one-off ’ methods,
and did not answer the question of how many fusions a
typical carcinoma expresses ([4,5] reviewed in [1]).
In addition to creating fusion genes, the abundant gen-
ome rearrangements in these cancers break many other
genes, and since breakage will almost always affect gene
function, rearrangement is likely to make a significant
contribution to inactivating genes [1,6].
Recent technical developments now allow systematic
searches for genome rearrangements and hence fusion
genes [1]. ‘Array painting’, i.e. hybridization of individual
chromosomes to a genomic microarray, allows many
chromosome rearrangements (though not inversions) to
be analyzed to almost 1kb resolution [7-9]. ‘Paired-end-
sequencing’ can be used to identify rearrangements by
finding breakpoint junctions: small genomic DNA frag-
ments, typically 250-500bp, are sequenced from both
ends and the paired sequence reads examined to see
whether they are the expected distance apart on the
reference genome [10-12]. A variation is ‘mate-pairs’,
where fragments of 3 to 5 kb are end-sequenced [11].
Paired-end sequencing is also being applied to cDNA to
find fusion transcripts directly [13-15].
To search for fusion genes in a representative breast
cancer we chose the ZR-75-30 breast cancer cell line
[16]. It has a typically rearranged karyotype, and a typ-
ical high-copy-number coamplification of parts of chro-
mosomes 8 and 17, particularly 8q24 and 17q11-24,
forming five homogeneously staining regions (hsrs) [17].
As often seen in breast cancer [18-22], this is a complex
coamplification of many small fragments of the genome.
The amplification is relevant to the search for fusion
genes as some amplifications harbour fusion genes, per-
haps formed early in cancer development and subse-
quently amplified [10,20,21]. ZR-75-30 is also of interest
as it is estrogen-receptor-positive (ER+) and has been
used as a model of an ER+ breast cancer that is insensi-
tive to tamoxifen, in contrast to the sensitive line ZR-75-
1 (which was from an unrelated patient) [16].
To find fusion transcripts in ZR-75-30, we refined our
previous 1-Mb resolution array-painting analysis of its
karyotype [8], using high-resolution array CGH data.
Then we applied paired-end sequencing to identify re-
arrangement junctions, particularly those in theamplification, which are preferentially sampled because
they are present in multiple copies.
Materials and methods
Nomenclature, genome positions and transcripts
Genome positions are relative to GRCh37/hg19. Exon
numbering is from the Ensembl transcripts listed in
Additional file 1. Gene names follow HUGO Gene No-
menclature and protein reference numbers are from
UniProtKB/Swiss-Prot database.
Cells, DNA, RNA
ZR-75-30 cells were as used previously [8,17], derived
from a sample frozen in 1999 by Dr M.J. O’Hare, Ludwig
institute for Cancer Research/UCL Breast Cancer La-
boratory, London, U.K., who had obtained them from
the American Type Culture Collection. We authenti-
cated them by STR (short tandem repeat) analysis, and
they matched the ATCC database at all eight specified
loci. Further evidence for their authenticity was that the
fusion genes we described were common to other stocks
of the line held by the ATCC and other laboratories (see
Results). The cells were maintained on 50:50 DMEM:F12
medium (Invitrogen, Grand Island, NY, USA), 10 μg/ml
insulin, 10% foetal bovine serum. Non-cancer breast cell
lines, used to investigate expression in normal breast,
were from the originators: HB4a is a line immortalized
from purified breast luminal epithelial cells [23] and the
HMT3522 line was from fibrocystic (non-cancer) breast
[24]. Other breast cancer cell lines were as described
[17,25]. Genomic DNA, total RNA and random-primed
cDNA were prepared as described [26].
Array-CGH data
Data were kindly provided by the Wellcome Trust Sanger
Institute [27]. Breakpoint intervals were judged by eye
and confirmed by segmentation using the PICNIC
algorithm [28].
Paired-end sequencing
ZR-75-30 genomic DNA was sequenced in paired-end
read mode using the Illumina GAIIx Genome Analyzer,
and HiSeq2000 (Illumina, Great Chesterford, UK)
[10,29]. Briefly, we sheared 5 μg of genomic DNA by
sonication using a Bioruptor sonicator (Diagenode,
Liège, Belgium). The fragmented DNA was end-repaired
and a 3’ overhang was created, followed by ligation
of Illumina paired-end adaptor oligonucleotides. We
size-selected fragments at 400–600 bp by agarose gel
electrophoresis, and enriched for fragments with primers
on either end by an 18-cycle PCR reaction. A total of
five flowcell lanes were sequenced. 43 million, 36-bp,
paired sequences (counting only unique reads with high-
quality mapping) were obtained from one 500 bp library
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age 1.7-fold coverage of single-copy breakpoints in this
subtetraploid genome.
Two additional paired-end sequencing libraries were
made by the ‘mate-pair’ approach [11]: 3kb DNA frag-
ments were circularized and the junction fragments iso-
lated as a paired-end library, using reagent kits supplied
by Illumina. A single lane of each 3 kb library was
sequenced, yielding about 1.25 million paired sequences,
equivalent to 0.5 X coverage of single-copy breaks.
Alignment and fusion prediction
In outline, analysis steps were: (i) alignment of sequen-
cing reads, (ii) identifying aberrant pairs of read pairs,
i.e. read pairs that aligned but not in the expected orien-
tation or separation, (iii) clustering concordant aberrant
reads to find candidate structural variants, and filtering
of those candidates, (iv) prediction and verification of fu-
sion genes.
Raw sequences were obtained from Illumina’s standard
image analysis (FIRECREST) and base calling modules
(BUSTARD). Reads were aligned to the reference gen-
ome GRCh37/hg19 with BWA [30] to identify and re-
move normal read pairs, which align to the genome with
the expected distance apart and orientation. Non-
normal reads were then realigned using Novoalign
(Novocraft Technologies, Selangor, Malaysia), a slower
but more thorough aligner. Novoalign gives each read a
mapping quality score, a measure of the confidence of
mapping, and read pairs in which either read scored
below 30 were discarded. Library preparation involved a
PCR amplification step which can result in duplicate
copies of the same read pair being sequenced: exact PCR
duplicates were identified, and all but one copy removed,
using Picard (http://picard.sourceforge.net/; [31]). This
gave ’aberrant read pairs’, read pairs that aligned but not
with normal separation and orientation. These were then
grouped into clusters of read pairs that were consistent
with the same rearrangement junction: a minimum of
two consistent reads were required. Additional filters
were then applied. Read pairs were checked for a pos-
sible normal match to the reference genome using BLAT
[32], since the alignment software sometimes aligns a
read to an homologous sequence instead of its true
match, perhaps because of sequencing errors or poly-
morphisms. Likely PCR duplicates that were offset by
one or two bp were also discarded as likely to be PCR
duplicates where a primer had lost one or two 3’ base
pairs. Known normal human copy number variations
[33] were discarded. Apparent variants were removed if
they also appeared in a pool of paired end sequences
from 18 other unrelated samples from cancers, normal
tissue or cell lines. Apparent intra-chromosomal rear-
rangements spanning less than 10kb were also discarded,as most would be polymorphisms or outsize fragments.
(Note that this does not remove all small rearrange-
ments, such as small apparent insertions, e.g. the two
apparent junctions between chromosome 1 at 109.65
Mb and a fragment of chr22 at 30.16Mb. Such ‘inser-
tions’ may be deletions in the reference genome).
Gene fusions and breakage were predicted from the
resulting rearrangement breakpoints using the Ensembl
Application Programming Interface http://www.ensembl.
org/info/docs/api/index.html to retrieve all the genes
that overlapped the breakpoints, or were adjacent to
breakpoints. To predict whether a fusion transcript
could be formed we considered whether the 5’ or 3’ end
of a gene would be retained, and whether, when the 5’
end of a gene was retained, a ‘runthrough’ fusion could
be formed by transcription into a downstream intact
gene near the junction.
Verification, Cloning and Sequencing of Junctions
Selected genomic junctions were verified by PCR using
primers designed to flank the junction (Additional file 2
and Additional file 3; Eurofins MWG Operon, Ebersberg,
Germany), using DNA pooled from twenty normal indivi-
duals as a control. To detect fusion transcripts, we
amplified from cDNA using primers in flanking exons
of the expected fusions. Selected full-length transcripts
were then amplified using primers designed to include
the putative start and stop codons. Amplification was for
35 cycles with an annealing temperature of 58°C using
HotMaster Taq DNA Polymerase (5 PRIME GmbH,
Hamburg, Germany) or, for long-range PCR, ElongaseW
Enzyme Mix (Invitrogen, Carlsbad, CA, USA) with 2mM
Mg2+. PCR products were sequenced in both directions,
generally after cloning using a TOPO TA cloning kit
(Invitrogen, Carlsbad, CA, USA). Primers used for clon-
ing genomic and cDNA junctions are given in Additional
file 4.
This study did not require ethical approval.
Results
Refined cytogenetic map of the ZR-75-30 genome
We first refined our previous analysis of the karyotype
of ZR-75-30 to ~10kb resolution. In our previous ana-
lysis we used array painting, in which chromosomes are
isolated by flow cytometry and hybridized individually to
genomic arrays, to identify the components of each
chromosome [8]. This had given us a map of inter-
chromosome rearrangements spanning more than about
3 Mb. This analysis was refined by matching the unba-
lanced breakpoints with array-comparative genomic
hybridization (array-CGH) on the SNP6 platform, from
Bignell et al. [27] (Additional file 5). Some additional
copy number steps, below the resolution of the array
painting, were revealed in the unamplified regions,
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most likely additional internal rearrangement of the 1;21
chromosome translocation named peak G in Howarth
et al. [8]) (Additional file 5 and Additional file 6).
We then overlaid a list of breakpoint junctions
obtained by paired-end sequencing (Additional file 5).A B
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data [8].
This strategy yielded 318 apparent genomic junctions
(Additional file 7), of which 112 were identified as likely
to explain a copy number step or match a junction in
the array painting data (Additional file 5). Of the 318
genomic junctions, we identified 47 that were predicted
to fuse genes, and tested for them by PCR on genomic
DNA. 37/47 junctions were successfully amplified,
among which 24/25 junctions were amplified that were
associated with copy number steps, compared to 13/22
that were not. 2 of these 13 junctions, not associated
with detectable copy number change, were also ampli-
fied from pooled normal genomic DNAs and therefore
were not considered further. The 125 genomic junctions
that had been confirmed by an associated copy number
step (89), or positive PCR product (13), or both (23), are
illustrated in Figure 1 and Additional file 2. 62% of these
are intra-chromosomal rearrangements.
We were able to identify breakpoint junctions corre-
sponding to most of the previously-known breakpoints:
about 55% of the breakpoints in unamplified regions,
and 97% of the breakpoints (identified from copy num-
ber steps) in the amplified regions of chromosome 8 and
17, which, because they are present in many copies, gave
more reads in the sequencing (Additional file 5 and
Additional file 7 and Figure 1).
The array-CGH showed that the coamplification of
chromosomes 8 and 17 was very complex (Figure 1C),
too complex for all the fragments and copy number
steps to be resolved. A reliable map of the amplicon can-
not be assembled from these junctions alone, because
not all junctions would have been detected, some may
be spurious, and there are usually multiple ways to as-
semble a given set of junctions into a linear map [34,35].
However, we show one possible assembly of 10 of the
junctions from chromosomes 8 and 17, to illustrate the
complexity (Additional file 8). There was also a junction,
verified by genomic PCR, that may well represent the
join between the 8;17 amplification and flanking
chromosome 14 material. It joins 84.97 Mb on chromo-
some 14 to 102.54 Mb on chromosome 8. All four chro-
mosomes that carry blocks of 8;17 coamplification also
carry 14q (chromosome fractions C,D, F and L in ref.
[8]), so this join may be the same on all of them.
Gene fusions
We found a total of 12 expressed gene fusions: we pre-
dicted 9 from paired-end sequencing, and we confirmed
a further 3 that were reported by Robinson DR et al. [15],
also identifying the structural rearrangements that had
generated these additional fusions.
Our nine fusion genes were found by searching junc-
tions computationally to identify potentially fused genes,followed by manual inspection (Additional file 7). Junc-
tions predicted to create fusions were verified by PCR
on genomic DNA, as above, and the predicted tran-
scripts were tested for by PCR from cDNA. Of thirty
predicted fusion transcripts, nine were successfully amp-
lified (Table 1, Figure 2; for junction sequences see
Additional file 1 and Additional file 3), including two of
thirteen predicted ‘run-through’ fusions, i.e. fusions
formed by breakage of the 5’ gene and transcription from
this gene into an intact downstream gene (Figure 2).
Some of the failures to amplify junctions and fusion
transcripts may have been technical failures, or due to
errors in mapping the paired sequences, or because the
rearrangements were more complex than the automated
analysis revealed.
We showed, by PCR, that all twelve of the fusions
were present in other available stocks of the ZR-75-30
cell line, and not recent evolution in our cultures. All
the fusion transcripts were present in the ZR-75-30
stock used in Robinson et al. [15], tested using RNA
kindly provided for the purpose by Prof Reis-Filho,
Breakthrough Breast Cancer Research Centre, Institute
of Cancer Research, London, UK (passage 5 after receipt
from ATCC), and in a separate stock from the Institute
of Cancer Research. Furthermore, the genomic junctions
that create the twelve fusions were all present in a DNA
sample newly purchased direct from ATCC.
As found previously in breast cancer cell lines [12,36],
a number of the genomic breakpoint junctions showed
microhomology (four out of seven sequenced junctions
had 1–4 bp of microhomology), and one contained a
small fragment of sequence inserted from elsewhere in
the genome, termed a ‘genomic shard’ [37] (Additional
file 3). This may be characteristic of a microhomology-
mediated break-induced-replication (MMBIR) mechanism
[38]. Our strategy may overlook some of these complex
junctions.
Of the 12 fusions (Figure 2), nine were from the coam-
plification of chromosomes 8 and 17. Four were ‘run-
through fusions’, where transcription runs from a broken
5’ gene into an intact downstream gene, with splicing
into the first splice acceptor, usually the second exon.
Two fusions spanned two or more junctions (Figure 2A
and B).
Fusion genes in the (8;17) amplicon
APPBP2-PHF20L1
Paired-end reads suggested a complex rearrangement
that joined part of APPBP2 and PHF20L1 (Figure 2A;
Additional file 7). We confirmed the presence of a
double junction at the genomic level by amplifying the
expected 10.4 kb APPBP2 insert by long-range PCR be-
tween chromosome 8 and PHF20L1-intron 2 (Additional
file 3).
Table 1 Verified expressed gene fusions in the breast cancer cell line ZR-75-30 predicted from structural analysis
5’ gene 3’ gene Chromosomes involved a Expression In
frame e
Fusion (F) or
Runthrough
fusion (R)
5’ 3’
APPBP2 PHF20L1 17 8 yes yes F
COL14A1 SKAP1 8 17 yes yes F
TAOK1 PCGF2 17 17 yes b,d yes F
USP32 CCDC49 17 17 yes d no F
BCAS3 HOXB9 17 17 yes d see text F
TRPS1 LASP1 8 17 yes yes R
ERBB2 BCAS3 17 17 yes c no R
DDX5 DEPDC 17 8 yes c yes R
PLEC1 ENPP2 8 8 yes c yes F
TIAM1 NRIP1 21 21 yes b yes F
ZMYM4 OPRD1 1 1 yes no F
TIMM23 ARHGAP32 10 11 yes no R
TMEM74 APPBP2 8 17 no F
TRAPPC9 STARD3 8 17 no F
SSH2 PLXDC1 17 17 no F
TAOK1 CA10 17 17 no F
HYLS1 TIMM23 11 10 no b F
USP32 RALYL 17 8 no F
TMEM74 ACACA 8 17 no F
NUDCD1 TAC4 8 17 no R
TRAPPC9 HOXB6 8 17 no R
SSH2 NFE2L1 17 17 no R
TTC35 MKS1 8 17 no R
TMEM71 CRYBA1 8 17 no R
CA3 KIAA1429 8 8 no R
GRHL2 NUDCD1 8 8 no R
SUPT6H GPIHBP1 8 17 no R
PGAP3 NOV 8 17 no R
KIAA0100 LY6H 8 17 no R
TG ERBB2 8 17 no R
All genomic junctions tested were positive by PCR; those marked c were not tested.
a Precise chromosomal positions are given in Additional file 2 and Additional file 5 and the exon structure in Figure 2.
b 5’ gene is untranslated sequence only.
c Fusions not predicted by our analysis but detected by transcriptome sequencing by Robinson et al. (2011) and confirmed here by RT-PCR. Genomic breakpoints
were detected in the present dataset on additional inspection—they had not met our stringent criteria or were complex rearrangements.
d Fusions also reported by Robinson et al. (2011).
e Predicted from annotations; not experimentally verified.
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of APPBP2 in frame to exon 3 of PHF20L1 Isoform 2
(ENST00000337920: the ENSEMBL transcripts from
which the exon numbering was taken are listed in
Additional file 1) (Figure 2A). Additionally, an alterna-
tively spliced, out-of-frame fusion transcript was detected
(Figure 2A).
This is likely to be only part of the fusion transcript,
since exon 5 is not a known transcription start site of
APPBP2. The upstream genomic junction (Figure 2A)
joins APPBP2 intron 4 to chromosome 8 at 109.67 Mb,but does not join it to any known gene—presumably
there is a further rearrangement junction upstream of
this.
COL14A1-SKAP1
A full-length fusion transcript was amplified in which
COL14A1 exon 2 was joined in frame to exon 5 of SKAP1
(Table 1, Figure 2A, Additional file 1 and Additional file 7).
Additional products were amplified that included cryp-
tic exons of varying length from within intron 4 of
SKAP1 (Figure 2A), but in these transcripts SKAP1 is
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Figure 2 Schematic representation of gene fusions and the expressed fusion transcripts in the breast cancer cell line ZR75-30 (not to
scale). A. Fusions in the 8;17 amplicon. B. Structure of fusion transcripts detected by Robinson et al. [15]. C. Fusions at single copy breaks.
Relevant exons are represented as numbered boxes, the transcription start site (AUG) is indicated with a black arrow and the breakpoint is
indicated with a zig-zag line at the approximate chromosomal position (based on the UCSC Genome Browser, hg19). The (sequenced) expressed
fusion transcripts and (where applicable) alternative splice products are shown below as black boxes joined by a dotted line. Exons depicted in
grey are expected to be expressed, but were not sequenced. For numbering of exons see Additional file 1.
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7 was found, introducing a stop codon in exon 8. Exon-
7-skipped transcripts were observed in other breast
cancer cell lines. It is not clear whether SKAP1 is upre-
gulated by fusion as its expression was very variable
among normal and breast cancer cell lines. In T lym-
phocytes SKAP1 is associated with ADAP, and ADAP
mRNA was detected in ZR-75-30 and other cell lines
with relatively high SKAP1 expression.TAOK1-PCGF2/MEL18, USP32-CCDC49, BCAS3-HOXB9,
TRPS1-LASP1
The TAOK1-PCGF2, USP32-CCDC49, and BCAS3-
HOXB9 fusion transcripts were detected by RT-PCR es-
sentially as expected (Figure 2A), except that the splice
donor and acceptor sites of TAOK1 and PCGF2 in their
fusion transcript were both offset a few base pairs from
the splice junctions reported by ENSEMBL (Additional
file 1). These three fusions were also detected by tran-
scriptome sequencing [15]. The TRPS1-LASP1 fusion
joins exon 3 of the transcription factor TRPS1, by tran-
scription running through, in frame, to exon 2 of LASP1
(Figure 2A).BCAS3-ERBB2, DDX5-DEPDC6/DEPTOR, PLEC1-ENPP2
These three fusion transcripts were not discovered by
our initial analysis. They were reported by Robinson
et al. [15], who detected 6 fusion transcripts in ZR-75-30
by sequencing cDNA, three of which we had found
(Table 1). The additional three fusion transcripts we
confirmed, by RT-PCR, and we also identified their gen-
omic junctions in our sequencing data (Figure 2B). We
had failed to discover two of these fusions because of
limitations of our fusion prediction: DDX5-DEPDC6/
DEPTOR is a ‘run-through’ fusion (see above) that had
been obscured by other possible downstream fusion
partners; while PLEC1-ENPP2 was formed by a complex
rearrangement apparently comprising two genomic junc-
tions (Figure 2B). The BCAS3-ERBB2 breakpoint junc-
tion was present only in one mate-pair library and
therefore had not met our stringent criteria.
Fusion genes not in the amplicon, TIAM1-NRIP1, TIMM23-
ARHGAP32, ZMYM4-OPRD1
The TIAM1-NRIP1 fusion was predicted both from
paired-end sequencing and from combining the array
painting with SNP6 array-CGH. It was probably formed
by a simple 16-Mb interstitial deletion on chromosome
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number in array CGH and absent from the array paint-
ing hybridisation of chromosome der(1)t(1;21)del(21)
(peak G in [8]). A full-length transcript was amplified,
with TIAM1 exon 1 fused to NRIP1 exon 2 (Table 1,
Figure 2C, Additional file 1).
The TIMM23-ARHGAP32 fusion is the result of a
translocation between chromosomes 10 and 11.
TIMM23 is broken and transcription runs into the intact
ARHGAP32 gene, joining exon 6 of TIMM23 to exon 2
of ARHGAP32 (Figure 2C).
The ZMYM4-OPRD1 fusion is the result of an internal
rearrangement of chromosome 1 (Table 1, Figure 2C,
Additional file 7). Two transcripts were observed, both
joining OPRD1 out of frame and leading to a stop codon
shortly after the breakpoint. A major transcript was
detected, fusing ZMYM4-exon 26 to OPRD1-exon 2 as
expected (Figure 2C), and a minor transcript, splicing
ZMYM4-exon 25 to OPRD1-exon 2 (Figure 2C).
We were unable to clone and sequence the ZMYM4-
OPRD1 genomic junction, but several junctions were
detected in this region of chromosome 1, suggesting that
the rearrangement may be complex.
Discussion
Analysis of the ZR-75-30 genome
Together, these data provide a gene-level analysis of
most of the unamplified genome rearrangements in this
cell line, of more than 10 kb span. A few details are still
missing, notably the centromeric breakpoints, and some
balanced breakpoints. Balanced breakpoints are invisible
to array-CGH and not all were sampled by the paired-
end sequencing or fine-mapped in our previous array
painting.
Paired-end sequencing has various limitations, and
combining with other structural data as we have done is
clearly valuable. Firstly, the method is not expected to
find all rearrangements, because it samples the genome
at random, and coverage is dependent on GC content
[29]. Also, reads in repeats and segmental duplications
generally cannot be used because they cannot be
mapped to a unique match in the reference genome.
Secondly, artefactual rearrangements can be created by
coligation of DNA fragments during preparation for se-
quencing, and by errors in mapping reads.
Sampling of junctions was surprisingly good: we
accounted for 97% of the copy number steps detected by
array-CGH in the amplicon, where the greater number
of reads across the junctions increased sensitivity. This
suggests that, even using only 36 bp reads, rather few
junctions would be undetectable because they are
flanked by non-unique sequences. The lower sampling
of single-copy junctions resulted in about 55% of the
junctions detected by array-CGH being detected bysequencing. Conversely, we identified almost twice as
many junctions in the amplicon as we expected from the
copy number steps. These were presumably a mixture of
artefacts and additional rearrangements that are not
resolved by CGH, either because they involve small frag-
ments or are balanced.
Another limitation of paired end sequencing is that it
does not show how junctions are joined together, e.g.
whether two apparently-neighbouring junctions are on
the same chromosome or not, nor whether the region
between is interrupted by further junctions [35]. This is
illustrated by two of the fusion genes, APPBP2-PHF20L1
and PLEC1-ENPP2, both transcribed across more than
one genomic junction.ZR-75-30 expresses at least 12 fusion transcripts
By combining molecular cytogenetic approaches—high-
resolution array-CGH and array painting—with paired-end
sequencing, we have catalogued genome rearrangements
of this cell line and found 9 expressed fusion transcripts.
We combined this with 3 additional fusion transcripts
found by sequencing cDNA [15], for which we have iden-
tified the genomic junctions.
Nine of 12 fusions in ZR-75-30 are in the complex
coamplification of chromosomes 8 and 17, the fusions
APPBP2-PHF20L1, BCAS3-HOXB9, TAOK1-PCGF2 and
DDX5-DEPDC6/DEPTOR being most amplified. Such
complex coamplifications are common [19] and prob-
ably give the ‘firestorm’ pattern of multiple small ampli-
fied fragments seen in array-CGH [22,39]. The MCF7
cell line has a similar coamplification involving chromo-
somes 1, 3, 17, and 20 and containing highly-amplified
gene fusions [6].
Of these 12 fusion genes, seven were formed by intra-
chromosomal rearrangements, confirming that more
fusion genes are formed by intra-chromosomal rearrange-
ment than by chromosome translocation [1]. This might
be expected if rearrangements arise at replication bubbles
[36] rather than random breakage and rejoining.How many expressed fusion genes are there in breast
cancers?
Extrapolating from our work and Robinson DR et al.
[15], ZR-75-30 may have around 18 expressed fusion
genes and breast cancers in general—not cell lines—may
express on average around 10.
In ZR-75-30, using structural analysis, we found half
of the six expressed fusions detected by Robinson DR
et al. [15], while, using cDNA sequencing, they found
three of the nine we detected—both figures suggest the
true total might be around 18. This is consistent with re-
cent, probably incomplete, figures from other cell lines:
20 expressed fusions have been verified in MCF7, with
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have been found in BT474 and 13 in SKBR3 [13].
Breast cancers—as opposed to cell lines—appear to
have almost as many fusions. Robinson DR et al. [15]
identified an average of 4.2 expressed fusions per case
(0 to 20 in 38 breast tumours), compared to 5.5 per case
in cell lines. Their sensitivity seems to have been around
40%, comparing their findings with ours and with the
published cell line data above. This gives a best guess
that breast tumours will on average express 10 fusions
[41], with wide variation from cases to case, as expected
from their variable levels of rearrangement [42].Are these passenger or driver mutations?
The fusions found here argue strongly that some at least
are selected, i.e. ‘driver’ mutations, rather than random
incidental ‘passenger’ mutations [43]. As detailed in the
supplementary discussion in Additional file 9, several of
the genes involved have already been found to be fused
in other breast cancer cell lines—PHF20L1 and BCAS3
[6,13,15,21,44] —or in other tumours—BCAS3 again,
and PCGF2, TAOK1 and TRPS1 [45,46]. Others are
members of families that include multiple fused genes—
the collagens, HOX and PHF families. Several of the
fusions resemble known recurrent gene fusions in gen-
eral functional terms [1,2]: for example, fusions of
HOXB9, PCGF2, PHF20L1, and NRIP1 would be typical
of the many known fusions that control gene expression
directly or via chromatin structure, and all could encode
functional domains of the proteins. Several of the genes
involved are also in signalling pathways relevant to
breast cancer: ERBB2, NRIP1 and BCAS3 are involved
in estrogen receptor function and APPBP2 with andro-
gen receptor; while TAOK1 and SKAP1 are involved in
MAPK signalling and DEPDC6/DEPTOR regulates
mTOR signalling.
Several of the fused genes are also recurrently broken
in a substantial proportion of breast cancers, as judged
by copy number steps in array-CGH of 1000 breast
tumours [47]: around 10% have breaks in ERBB2,
BCAS3 and SKAP1, while COL14A1, TIAM1, USP32,
TAOK1 are broken in around 4%.
Some of the fusions, and particularly those not
expressed, may simply inactivate a copy of the participat-
ing gene(s) [1,6]. For example, our fusions of TIAM1
and TAOK1 inactivate one copy of these genes. Some
genes, e.g. BCAS3, that are fused in more than one can-
cer cell line retain different, non-overlapping parts of the
gene in different cases, suggesting the common theme is
inactivation. In some cases fusion of a gene may sup-
press its expression, perhaps by destabilising the mRNA:
among the predicted fusion genes for which we could
not detect a transcript, unfused copies of some of the 5’participating genes were transcribed—for example SSH2,
NUDCD1 and TRAPPC9 (Table 1; Additional file 7).
Conclusion
Fusion genes in ZR-75-30 and cancers in general
We have brought the total of fusion genes expressed by
ZR-75-30 to 12, and there are good reasons to think the
final total will be around 18. We have argued from this
and other data that carcinomas not only have fusion
genes analogous to those found in leukaemias [1,4], but
each case may have many of them, and many will be
functionally significant. This suggests a picture of neo-
plasia in which all neoplasms have a mixture of mutation
types—point mutations, deletions, fusion genes, etc. Ra-
ther than leukaemias being driven by fusion genes while
carcinomas were driven by point mutations and dele-
tions, the main difference between carcinomas and leu-
kaemias may simply be that carcinomas have more
mutations than leukaemias.
Additional files
Additional file 1: Junction and fusion transcript sequences.
Additional file 2: Confirmed structural variants in ZR-75-30.
Additional file 3: Genomic junction sequences.
Additional file 4: Primers for amplifying genomic or transcript
junctions and full-length fusion genes.
Additional file 5: A comparison of breakpoints determined by snp6
and solexa sequencing.
Additional file 6: A comparison of breakpoints by 1Mb array
painting and solexa sequencing data.
Additional file 7: Structural rearrangements determined by paired-
end sequencing.
Additional file 8: One possible assembly of ten junctions in the
8;17 amplicon of ZR-75-30.
Additional file 9: Supplementary discussion: Discussion of
individual fusion genes.
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